Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Vanda's Licenses CFTR Modulators From UCSF, But Not For Cystic Fibrosis

Executive Summary

Intellectual property licensed from UCSF focuses on non-mutated, wild-type CFTR activators and inhibitors, thought to offer potential in ophthalmic, renal and gastrointestinal indications.

You may also be interested in...



Vanda And Nektar Persevere With Fanapt And Onzeald In EU

The two products that the European Medicines Agency’s key scientific committee, the CHMP, decided last week should not be approved in the EU were Vanda’s schizophrenia treatment Fanaptum (iloperidone), and Onzeald (etirinotecan pegol), a potentially new treatment for breast cancer with brain metastases from Nektar/Daiichi Sankyo Europe. The companies want the CHMP to look again at the negative opinions they received.

Tech Transfer Roundup: Ohio State Turns To Industry Exec To Optimize Assets Before A Deal

Jeffrey Patrick joins Ohio State's effort to develop cancer drugs from internal research, bringing a biopharma viewpoint to optimizing such programs before the deal-making effort starts. Plus, the EMA sets a framework for academic interaction, and more tech transfer news.

Deal Watch: Merck, Incyte Double Down On Keytruda/Epacadostat Collaboration

Expansion of 2015 development partnership adds lung and bladder cancer as well as renal and head-and-neck carcinoma to trials of the two immuno-oncology drugs. Jazz licenses Japanese rights to two of its commercial products to Nippon Shinyaku.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

SC098486

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel